Bio-Techne Aktie
54,66USD | 0,34USD | 0,62% |
WKN DE: A12ENG / ISIN: US09073M1045
Personal
2021 | 2022 | 2023 | 2024 | 2025 | |
---|---|---|---|---|---|
Personal am Ende des Jahres | 2 600 | 3 000 | 3 050 | 3 100 | 3 100 |
Umsatz pro Mitarbeiter in Mio. EUR | 0,36 | 0,37 | 0,37 | 0,37 | 0,39 |
Bilanz (in Mio. USD) - Aktiva
2021 | 2022 | 2023 | 2024 | 2025 | |
---|---|---|---|---|---|
Summe Umlaufvermögen | 511 | 606 | 621 | 617 | 608 |
Summe Anlagevermögen | 1 839 | 1 765 | 2 112 | 2 196 | 1 950 |
Summe Aktiva | 2 350 | 2 371 | 2 734 | 2 813 | 2 558 |
Bilanz (in Mio. USD) - Passiva
2021 | 2022 | 2023 | 2024 | 2025 | |
---|---|---|---|---|---|
Summe Fremdkapital | 779 | 670 | 767 | 744 | 639 |
Summe Eigenkapital | 1 571 | 1 701 | 1 967 | 2 069 | 1 919 |
Summe Passiva | 2 350 | 2 371 | 2 734 | 2 813 | 2 558 |
Adresse
614 McKinley Place NE, 55413-2610 Minneapolis | |
Telefon | +1 (612) 379-8854 |
Internet | http://www.bio-techne.com |
Management
Alpna H. Seth
Independent Director |
Amy E. Herr
Independent Director |
Cheryl Bethune
Chief Human Resources Officer & Senior VP |
David Clair
VP-Investor Relations & Corporate Development |
Gary Latham
Chief Technology Officer & Vice President |
James T. Hippel
Chief Financial Officer & Executive Vice President |
John L. Higgins
Independent Director |
Joseph D. Keegan
Independent Director |
Judith Klimovsky
Independent Director |
Julie L. Bushman
Independent Director |
Kim Kelderman
President, Chief Executive Officer & Director |
Martin Wirtz
Senior VP-Strategy & Corporate Development |
Matthew F. McManus
President-Diagnostics & Genomics Segment |
Qi Cheng
Vice President-Quality & Regulatory |
Robert V. Baumgartner
Chairman |
Roeland Nusse
Independent Director |
Shane V. Bohnen
Secretary, Chief Sustainability Officer & SVP |
Steven C. Crouse
SVP & GM-Analytical Solutions Division |
William A. Geist
President-Protein Sciences Segment |